Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

[1]  M. Goetz,et al.  Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen , 2010, Cancer.

[2]  Lang Li,et al.  Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort , 2009, Breast Cancer Research and Treatment.

[3]  A. Hofman,et al.  The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users , 2009, Breast Cancer Research and Treatment.

[4]  J. Cuzick,et al.  Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[5]  V. Jordan,et al.  Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. , 2008, Clinical breast cancer.

[6]  S. Lundgren,et al.  Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. Natarajan,et al.  Tamoxifen, hot flashes and recurrence in breast cancer , 2008, Breast Cancer Research and Treatment.

[8]  Wolfgang Simon,et al.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Amin,et al.  Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases , 2007, Drug Metabolism and Disposition.

[10]  S. Wingren,et al.  Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer , 2007, Breast Cancer Research.

[11]  Zeruesenay Desta,et al.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.

[12]  C. Falany,et al.  Pharmacogenetics of human cytosolic sulfotransferases , 2006, Oncogene.

[13]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[14]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[16]  D. Timmerman,et al.  Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Scheys,et al.  Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients , 2005, Breast Cancer Research and Treatment.

[18]  L. Skoog,et al.  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients , 2005, Breast Cancer Research.

[19]  E. van Limbergen,et al.  Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients , 2004, Anti-cancer drugs.

[20]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[22]  A. Luini,et al.  A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. , 2003, Journal of the National Cancer Institute.

[23]  G. Kearns,et al.  Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. , 1999, Pharmacogenetics.

[24]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[25]  P. Lønning,et al.  Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  P. Neven,et al.  TAMOXIFEN AND THE UTERUS AND ENDOMETRIUM , 1989, The Lancet.

[27]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[28]  P. Ueland,et al.  Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. , 1988, Cancer research.